---
title: "BUZZ-Tandem Diabetes steadies after boosted $265 mln convertible bonds sale"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/276898102.md"
datetime: "2026-02-25T13:57:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276898102.md)
  - [en](https://longbridge.com/en/news/276898102.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276898102.md)
---

# BUZZ-Tandem Diabetes steadies after boosted $265 mln convertible bonds sale

Tandem Diabetes Care (TNDM.O) shares trading around the flat line premarket after securing more capital than planned

San Diego, California-based insulin delivery systems manufacturer early Weds

private offering of $265 mln 0% 6-yr convertible bonds

Initial conversion price of $36.99 is 37.5% premium over stock’s last close of $26.90 TNDM shares fell 4.8% on Tues after co late Mon unveiled $200 mln offering for general purposes, including acquisitions or strategic investments, among other uses

Co to use $13.5 mln of proceeds to pay cost of capped calls; initial cap price set at $47.08, 75% above stock’s last close Through Tues, TNDM shares up 45% since co posted Q4 sales and adj operating income above LSEG estimates

Stock up 22% YTD as of last close after 39% drop in 2025

Avg rating of 24 analysts is “buy”; median PT $26, per LSEG data (Lance Tupper is a Reuters market analyst. The views expressed are his own)

### Related Stocks

- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [TNDM.US](https://longbridge.com/en/quote/TNDM.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)

## Related News & Research

- [Stryker to Acquire Amplitude Vascular Systems](https://longbridge.com/en/news/282548873.md)
- [Is Thermo Fisher (TMO) Quietly Rewiring Its AI Strategy Through New Data and Proteomics Alliances?](https://longbridge.com/en/news/282768343.md)
- [Nexalin targets Q2 FDA Q-Submission update for Alzheimer’s De Novo pathway](https://longbridge.com/en/news/282859210.md)
- [BUZZ-Street View: Analysts upbeat on Revolution pancreatic cancer drug](https://longbridge.com/en/news/282702171.md)
- [FDA Rejection Sparks Questions On Replimune Drug Approval Path](https://longbridge.com/en/news/282577359.md)